Cost-effectiveness study of treatment with biologic disease-modifying antirheumatic drugs in adult patients with active ankylosing spondylitis

Objective: to conduct a cost-effectiveness study of major biologic disease-modifying antirheumatic drugs (bDMARDs) used for the treatment of ankylosing spondylitis (AS) in Russian health care system with the focus on the new effective drug netakimab (NTK).

Patients and methods. Based on the available meta-analysis, a Markov model for therapy was constructed using reference drugs. Then, based on the simulation results, a Cost-Effectiveness Analysis (CEA) and a Budget Impact Analysis (BIA) were carried out. The robustness of the result has been confirmed by several sensitivity analyzes.

Results and discussion. NTK showed an advantage in CEA, including the cases when the direct costs of therapy were lower for the reference drug (which shows the greater efficacy of NTK). According to the BIA, the extension of NTK administration in naive patients was consistently associated with a decrease in the budgetary burden. Sensitivity analyzes confirmed the robustness of the result.

Conclusion. NTK has clinical and economic advantage in the treatment of AS, it is attractive in terms of both patient's and health care benefit in general. More extensive use of NTK can save more than 5 billion RUB.

1. Erdes ShF. Basic principles of therapy for ankylosing spondylitis (Bekhterev's disease). Nauchno-prakticheskaya revmatologiya. 2013;51(6):686-95. (In Russ.).

2. All-Russian public organization Association of Rheumatologists of Russia. Federal clinical guidelines for the diagnosis and treatment of ankylosing spondylitis (Bekhterev's disease) 2013. https://rheumatolog.ru/sites/default/files/Pdf/clinrec/ankiloziruyushchiy_spondilit.doc (дата обращения: 20.12.2020).

3. Smolen JS, Braun J, Dougados M, et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis. 2014 Jan;73(1):6-16. doi: 10.1136/annrheumdis-2013-203419. Epub 2013 Jun 8.

4. Galushko EA, Nasonov EL. Prevalence of rheumatic diseases in Russia. Al'manakh klinicheskoi meditsiny. 2018;(1):32-9. (In Russ.).

5. Lila AM, Dreval' RO, Inamova OV, et al. Medical and economic analysis of the impact of rheumatoid disease-associated disability on the country's economy in terms of implementation of pension reforms. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2019;14(4):18-25. (In Russ.). doi: 10.14412/1996-7012-2019-4-18-25.

6. Van der Heijde D, Dougados M, Davis J, et al. Assessment in Ankylosing Spondylitis International Working Group/Spondylitis Association of America recommendations for conducting clinical trials in ankylosing spondylitis. Arthritis Rheum. 2005 Feb;52(2): 386-94. doi: 10.1002/art.20790.

7. Betts KA, Griffith J, Song Y, et al. Network Meta-Analysis and Cost Per Responder of Tumor Necrosis Factor-α and Interleukin Inhibitors in the Treatment of Active Ankylosing Spondylitis. Rheumatol Ther. 2016 Dec;3(2):323-36. doi: 10.1007/s40744-016-0038-y. Epub 2016 Jul 25.

8. Van Tubergen A. Comparison of statistically derived ASAS improvement criteria for ankylosing spondylitis with clinically relevant improvement according to an expert panel. Ann Rheum Dis. 2003 Mar;62(3):215-21. doi: 10.1136/ard.62.3.215.

9. Pavy S, Brophy S, Calin A. Establishment of the minimum clinically important difference for the bath ankylosing spondylitis indices: a prospective study. J Rheumatol. 2005 Jan;32(1):80-5.

10. Calin A, Garrett S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994 Dec;21(12):2281-5.

11. Nas K. Relationship Between Clinical Findings, Quality of Life and Functional Disability Related to Disease Activity in Patients with Ankylosing Spondylitis. Turk J Rheumat. 2011;26(1):29-37. doi:10.5606/tjr.2011.005.

12. Brandt J. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. Rheumatology (Oxford). 2005 Mar;44(3):342-8. doi: 10.1093/rheumatology/keh475. Epub 2004 Nov 23.

13. Chen C, Zhang X, Xiao L, et al. Comparative Effectiveness of Biologic Therapy Regimens for Ankylosing Spondylitis. Medicine (Baltimore). 2016 Mar;95(11):e3060. doi: 10.1097/MD.0000000000003060.

14. http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=263e668f-ab60-4af8-b7ca5ce473921380&t=

15. http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=ccbb23a7-3ac6-46bf90b6-4e83a490397d&t=

16. http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=85819ef9-3707-4518-9065-d0fc4683ef37&t=

17. http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=746b5102-84c9-4d7e9d83-e07c10ad8d76&t=

18. http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=4deb438a-b96e-4588-9e56-66addd6d0155&t=

19. http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=f8bf42e1-d578-459fa3c6-fede76e3c51f&t=

20. http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=28f37b23-eb90-4d19-9465-a00b9efd48d6&t=

21. http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=0502dd45-775a-44e2-b812-15a1615a101a&t=

22. Dubinina TV, Gaidukova IZ, Sokolova VD, et al. Efficacy and safety of genetically engineered biological drugs in ankylosing spondylitis: a systematic review and metaanalysis of drugs registered in the Russian Federation. Nauchno-prakticheskaya revmatologiya. 2020;58(6):646-57. (In Russ.).

23. Industry standard «Clinical and economic research. General Provisions» Order of the Ministry of Health of the Russian Federation of 27.05.2002 №163 together with OST 91500.14.0001-2002.

24. Methodological recommendations for conducting a comparative clinical and economic evaluation of a medicinal product. Approved by the order of the fgbi «CEKKMP» Ministry of health of Russia from 29 Dec 2018, №242- od. https://rosmedex.ru/wp-content/uploads/2019/06/MR-KE%60I_novayaredaktsiya_2018-g..pdf

25. Methodological recommendations for assessing the impact on the budget as part of the implementation of the program of state guarantees of free provision of medical care to citizens. Approved by the order of the fgbi «CEKKMP» Ministry of health of Russia from 29 Dec 2018, №242-od. https://rosmedex.ru/wpcontent/uploads/2019/06/MR-AVB_novaya-redaktsiya_2018-g..pdf.

26. Lila AM, Dreval' RO, Shipitsyn VV. Assessment of organization of medical care and drug provision for patients with rheumatic diseases, and the socioeconomic burden of these diseases in the Russian Federation. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2018;12(3):112-9. (In Russ.). doi:10.14412/1996-7012-2018-3-112-119.

27. http://www.gks.ru

28. Rumyantseva DG, Podryadnova MV, Rumyantseva OA, et al. Severe course of ankylosing spondylitis with resistance to drug therapy. Nauchno-prakticheskaya revmatologiya. 2020;58(2):232-7. (In Russ.).

29. Lorenzin M, Ortolan A, Frallonardo P, et al. Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab. BMC Musculoskelet Disord. 2015 Jul 24;16:166. doi: 10.1186/s12891-015-0620-4.

30. Ягудина Yagudina RI, Kulikov AYu, Serpik VG. Discounting in conducting pharmacoeconomic studies. Farmakoekonomika. Sovremennaya farmakoekonomika i farmakoepidemiologiya. 2009;(4):10-3. (In Russ.).

31. Schwartz R. Biological Modeling and Simulation: A Survey of Practical Models, Algorithms, and Numerical Methods. London: MIT Press; 2008. 408 p.

32. Naimark DM, Kabboul NN, Krahn MD. The Half-Cycle Correction Revisited. Med Decis Making. 2013 Oct;33(7):961-70. doi: 10.1177/0272989X13501558.

33. Blair HA. Secukinumab: A Review in Ankylosing Spondylitis. Drugs. 2019 Mar;79(4):433-43. doi: 10.1007/s40265-019-01075-3.

34. Fedyaev DV, Derkach EV, Frolov MYu. Clinical and economic analysis of the use of secukinumab in patients with ankylosing spondylitis. Meditsinskie tekhnologii. Otsenka i vybor. 2016;(3):42-53. (In Russ.).

35. https://www.cosentyx.com/ankylosingspondylitis/treatment-dosing

36. Mazurov VI, Ilyushina LV, Dolgikh SV, et al. The use of infliximab in the treatment of ankylosing spondylitis. Vestnik SeveroZapadnogo gosudarstvennogo meditsinskogo universiteta im. I.I. Mechnikova. 2012;(3): 99-107. (In Russ.).

37. Lytkina KA, Arutyunov GP. Experience with long-term use of certolizumab pegol (Cimzia). Sovremennaya revmatologiya = Modern Rheumatology Journal. 2013;7(3):50-3. (In Russ.). doi:10.14412/1996-7012-2013-14.

38. Erdes ShF. Certolizumab pegol in the treatment of axial spondyloarthritis. Nauchnoprakticheskaya revmatologiya. 2015;53(6): 641-5. (In Russ.).